What are Primary Malignant Thymic Neuroendocrine Tumours?
Primary Malignant Tumours of the Thymic Neuroendocrine type are rare cancers that arise from neuroendocrine cells within the thymus. The thymus is a small organ located in the upper chest behind the breastbone, and it plays an important role in immune system development during childhood.
These tumours are different from thymoma and thymic carcinoma. While thymoma and thymic carcinoma originate from thymic epithelial cells, thymic neuroendocrine tumours arise from hormone-producing neuroendocrine cells present within the thymus.
They are part of the broader group of neuroendocrine tumours and can range from well-differentiated tumours to highly aggressive neuroendocrine carcinomas.
Incidence
Thymic neuroendocrine tumours are extremely rare. They occur more commonly in adults, particularly in middle-aged men. In some cases, they are associated with genetic syndromes such as Multiple Endocrine Neoplasia type 1, where multiple endocrine glands develop tumours.
Because of their rarity, many cases are diagnosed at advanced stages.
Symptoms
Symptoms often result from pressure of the tumour on nearby chest structures. Patients may experience chest pain, cough, shortness of breath, or difficulty swallowing.
Some tumours produce hormones, leading to systemic symptoms. In rare cases, patients may develop features of Cushing’s syndrome due to excess hormone production. However, many patients present with vague symptoms, leading to delayed diagnosis.
Diagnosis
Imaging studies such as CT scan or MRI of the chest usually detect a mass in the anterior mediastinum, where the thymus is located. PET scans may help evaluate spread.
Definitive diagnosis requires biopsy. Under the microscope, the tumour shows neuroendocrine features and tests positive for neuroendocrine markers. It is important to distinguish these tumours from thymoma, thymic carcinoma, and metastatic neuroendocrine tumours from other organs.
Treatment
The primary treatment is complete surgical removal whenever possible. Because these tumours are often aggressive, additional treatments such as chemotherapy or radiation therapy may be required.
In advanced or metastatic disease, systemic therapy similar to that used for other neuroendocrine carcinomas may be administered.
Prognosis
The prognosis varies depending on tumour grade and stage. Well-differentiated tumours may grow more slowly, while poorly differentiated neuroendocrine carcinomas behave aggressively.
You can help us with your donation:
Without a Ribbon is a charity that works hard to aid those who suffer from rare cancers. You can help our cause in a variety of ways: